2022
584 Evaluation of a composite immunotherapy signature in non-small cell lung cancer patients treated with atezolizumab
Tolba K, Gandara D, Montesion M, Nabet B, Srivastava M, Albacker L, Redman M, Kozono D, Cummings C, Herbst R, Shames D, Fabrizio D. 584 Evaluation of a composite immunotherapy signature in non-small cell lung cancer patients treated with atezolizumab. 2022, a611-a611. DOI: 10.1136/jitc-2022-sitc2022.0584.Peer-Reviewed Original Research
2020
NSCLC: Integrating the “Yale model shared decision-making solution” into the practice setting.
Adelson K, Herbst R, Peterson P, Ingram M, Oliver B, Agrawal T, Davies M, Rudell E. NSCLC: Integrating the “Yale model shared decision-making solution” into the practice setting. Journal Of Clinical Oncology 2020, 38: 7054-7054. DOI: 10.1200/jco.2020.38.15_suppl.7054.Peer-Reviewed Original ResearchCheckpoint inhibitor therapyReasonable treatment optionMore side effectsLung cancer patientsCancer care settingsPatient-centered careTreatment decision processNational Quality ForumInhibitor therapyPatient-centric careCancer patientsTreatment optionsTreatment choicePost-intervention interviewsPatientsSide effectsPractice settingsQuality ForumSDM skillsHealthcare decisionsCareSDM processGreater improvementCliniciansTeam members
2018
Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer
Ruder D, Papadimitrakopoulou V, Shien K, Behrens C, Kalhor N, Chen H, Shen L, Lee JJ, Hong WK, Tang X, Girard L, Minna JD, Diao L, Wang J, Mino B, Villalobos P, Rodriguez-Canales J, Hanson NE, Sun J, Miller V, Greenbowe J, Frampton G, Herbst RS, Baladandayuthapani V, Wistuba II, Izzo JG. Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer. Oncotarget 2018, 9: 33995-34008. PMID: 30338041, PMCID: PMC6188056, DOI: 10.18632/oncotarget.26129.Peer-Reviewed Original ResearchLung cancerAdvanced non-small cell lung cancer (NSCLC) patientsNon-small cell lung cancer patientsNon-small cell lung cancerCell lung cancer patientsSubset of NSCLCWorse overall survivalCell lung cancerLung cancer patientsAnti-tumor effectsNovel therapeutic strategiesNSCLC cell linesTherapeutic paradigm shiftMAPK pathwayUnique therapeutic vulnerabilitiesOverall survivalCancer patientsClinical trialsLung adenocarcinomaKRAS/Therapeutic strategiesPharmacologic inhibitionTherapeutic vulnerabilitiesTherapeutic opportunitiesConcomitant targeting
2017
Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and -010.
Hellmann M, Ma J, Garon E, Hui R, Gandhi L, Soria J, Anderson K, Lubiniecki G, Piperdi B, Herbst R. Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and -010. Journal Of Clinical Oncology 2017, 35: 77-77. DOI: 10.1200/jco.2017.35.7_suppl.77.Peer-Reviewed Original ResearchNon-small cell lung cancerLong-term survival ratesLong-term survivalAdvanced non-small cell lung cancerKEYNOTE-001KEYNOTE-010PD-L1Survival rateOverall survivalLong-term benefitsLong-term survival modelsNon-small cell lung cancer patientsCell lung cancer patientsPercentage of patientsSurvival modelsCell lung cancerLung cancer patientsTreat populationDocetaxel armPembrolizumab monotherapyParametric survival modelsCancer patientsLung cancerPatientsSubsequent independent validation
2016
Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors.
Gettinger S, Zhang X, Homer R, Possick J, Wurtz A, Goldberg S, Chiang A, Herbst R, Rubinowitz A. Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors. Journal Of Clinical Oncology 2016, 34: 9030-9030. DOI: 10.1200/jco.2016.34.15_suppl.9030.Peer-Reviewed Original Research
2015
Lung Cancer in the Era of Precision Medicine
Politi K, Herbst RS. Lung Cancer in the Era of Precision Medicine. Clinical Cancer Research 2015, 21: 2213-2220. PMID: 25979927, PMCID: PMC4505624, DOI: 10.1158/1078-0432.ccr-14-2748.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsLung cancerClinical trialsBiomarker-driven clinical trialsLung cancer clinicEfficacy of immunotherapyLung cancer patientsLung cancer subtypesNovel therapeutic targetPrecision medicineFirst-generation drugsMetastatic diseaseCancer patientsEGFR mutationsCancer clinicActionable mutationsTherapeutic targetPatientsMolecular testingCancer subtypesImmune systemNew treatmentsMolecular subgroupsDrug resistanceMechanisms of sensitivityCancer
2014
Emerging Science and Therapies in Non-small-Cell Lung Cancer: Targeting the MET Pathway
Kris MG, Arenberg DA, Herbst RS, Riely GJ. Emerging Science and Therapies in Non-small-Cell Lung Cancer: Targeting the MET Pathway. Clinical Lung Cancer 2014, 15: 475. PMID: 25306384, DOI: 10.1016/j.cllc.2014.08.001.Peer-Reviewed Original ResearchConceptsCell lung cancerLung cancerMET pathwayNon-small cell lung cancerCME activitiesProgression-free survivalLung cancer patientsLung cancer specialistsCare of patientsIndividualized treatment strategiesLung cancer mutationsClinical research advancesQuality of lifeCollection of diseasesFree survivalMedical oncologistsCancer patientsCancer specialistsPatient outcomesTreatment strategiesHealthcare cliniciansCancer cell mutationsPatientsTissue acquisitionMET expression119IN Novel Molecular Studies to Inform the Conduct of Oncology Clinical Trials: from Battle to Master Protocols
Herbst R. 119IN Novel Molecular Studies to Inform the Conduct of Oncology Clinical Trials: from Battle to Master Protocols. Annals Of Oncology 2014, 25: iv41. DOI: 10.1093/annonc/mdu317.1.Peer-Reviewed Original ResearchLung cancer patientsCancer patientsSquamous cell lung cancer patientsMaster protocolsMulticenter phase 2 trialCell lung cancer patientsNovel molecular studiesPhase 2 trialScreen failure rateOncology clinical trialsCause of deathEffective treatment regimensIdentification of therapiesClinical trial researchIndividual patient's cancerSystemic chemotherapyClinical characteristicsMetastatic diseaseMost patientsPerformance statusTreatment regimensMultiple therapiesClinical trialsAdaptive randomization designPatient's cancerVandetanib and Indwelling Pleural Catheter for Non–Small-Cell Lung Cancer With Recurrent Malignant Pleural Effusion
Massarelli E, Onn A, Marom EM, Alden CM, Liu DD, Tran HT, Mino B, Wistuba II, Faiz SA, Bashoura L, Eapen GA, Morice RC, Lee J, Hong WK, Herbst RS, Jimenez CA. Vandetanib and Indwelling Pleural Catheter for Non–Small-Cell Lung Cancer With Recurrent Malignant Pleural Effusion. Clinical Lung Cancer 2014, 15: 379-386. PMID: 24913066, PMCID: PMC4160385, DOI: 10.1016/j.cllc.2014.04.002.Peer-Reviewed Original ResearchConceptsRecurrent malignant pleural effusionCell lung cancer patientsMalignant pleural effusionLung cancer patientsCell lung cancerPleural effusionCancer patientsMedian timeCatheter placementLung cancerEastern Cooperative Oncology Group performance statusPoor overall median survivalEnd pointSingle-arm phase II clinical trialPhase II clinical trialIndwelling pleural catheterOverall median survivalPrimary end pointSecondary end pointsDaily oral doseWeeks of treatmentPleural fluid cytologyVEGF receptor inhibitorPleural fluid cytokinesEligible patients
2013
Practice Patterns and Perceptions of Thoracic Oncology Providers on Tobacco Use and Cessation in Cancer Patients
Warren GW, Marshall JR, Cummings KM, Toll B, Gritz ER, Hutson A, Dibaj S, Herbst R, Dresler C, Committee I. Practice Patterns and Perceptions of Thoracic Oncology Providers on Tobacco Use and Cessation in Cancer Patients. Journal Of Thoracic Oncology 2013, 8: 543-548. PMID: 23529191, PMCID: PMC3628367, DOI: 10.1097/jto.0b013e318288dc96.Peer-Reviewed Original ResearchConceptsCancer patientsTobacco useOncology providersPractice patternsClinical careInitial patient visitTobacco cessation activitiesLung cancer patientsTobacco cessation methodsCessation activitiesMedication optionsCessation assistanceCessation interventionsPoor outcomeSmoking cessationTobacco cessationCessation effortsCancer careLung cancerCessation methodsAffect OutcomesPatient visitsPhysician respondentsTobacco assessmentClinician educationClinical and Biomarker Outcomes of the Phase II Vandetanib Study from the BATTLE Trial
Tsao AS, Liu S, Lee JJ, Alden CM, Blumenschein GR, Herbst R, Davis SE, Kim E, Lippman S, Heymach J, Tran H, Tang X, Wistuba I, Hong WK. Clinical and Biomarker Outcomes of the Phase II Vandetanib Study from the BATTLE Trial. Journal Of Thoracic Oncology 2013, 8: 658-661. PMID: 23584298, PMCID: PMC5118909, DOI: 10.1097/jto.0b013e31828d08ae.Peer-Reviewed Original ResearchMeSH KeywordsAcute-Phase ProteinsAgedAntineoplastic AgentsBiomarkers, TumorCarcinoma, Non-Small-Cell LungDisease-Free SurvivalFemaleGene AmplificationGenes, erbB-1HumansInterleukin-9Kaplan-Meier EstimateLipocalin-2LipocalinsLung NeoplasmsMaleMiddle AgedMutationPiperidinesProportional Hazards ModelsProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)QuinazolinesRas ProteinsTNF-Related Apoptosis-Inducing LigandConceptsDisease control rateWorse OSShorter PFSControl rateMutation patientsDual epidermal growth factor receptorVascular endothelial growth factor receptor inhibitionLung Cancer Elimination (BATTLE) trialNeutrophil gelatinase-associated lipocalinCell lung cancer patientsGrowth factor receptor inhibitionPhase II trialGelatinase-associated lipocalinLung cancer patientsTumor core biopsiesSerum biomarker analysisEGFR mutation patientsEpidermal growth factor receptorEGFR gene amplificationApoptosis-inducing ligandGrowth factor receptorMedian PFSOS benefitEpidermal growth factor receptor tyrosine kinaseII trial
2012
Clinical Outcomes and Biomarker Profiles of Elderly Pretreated NSCLC Patients from the BATTLE Trial
Tsao AS, Liu S, Lee JJ, Alden C, Blumenschein G, Herbst R, Davis SE, Kim E, Lippman S, Stewart D, Tang XM, Wistuba I, Hong WK. Clinical Outcomes and Biomarker Profiles of Elderly Pretreated NSCLC Patients from the BATTLE Trial. Journal Of Thoracic Oncology 2012, 7: 1645-1652. PMID: 23059780, PMCID: PMC5161038, DOI: 10.1097/jto.0b013e31826910ff.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBexaroteneBiomarkers, TumorCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellDrug Resistance, NeoplasmErlotinib HydrochlorideFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoplasm StagingNiacinamidePhenylurea CompoundsPiperidinesPrognosisQuinazolinesRetrospective StudiesSalvage TherapySorafenibSurvival RateTetrahydronaphthalenesConceptsProgression-free survivalDisease control rateNSCLC patientsOverall survivalElderly menGrade 3Older womenOlder menBetter median progression-free survivalHigher disease control rateLung Cancer Elimination (BATTLE) trialMedian progression-free survivalAge groupsBetter progression-free survivalCell lung cancer patientsBiomarker-Integrated ApproachesBiopsy-related pneumothoraxElderly NSCLC patientsMore grade 3Treatment-related deathsTumor tissue biomarkersRetrospective subgroup analysisSubset of patientsHigher overall survivalLung cancer patientsL4.1 Evolution of Battle Trials at Md Anderson Cancer Center
Hong W, Kim E, Herbst R, Papadimitrakopoulou V, Gold K, Wistuba I, Lee J, Lippman S. L4.1 Evolution of Battle Trials at Md Anderson Cancer Center. Annals Of Oncology 2012, 23: v7. DOI: 10.1016/s0923-7534(20)31272-2.Peer-Reviewed Original ResearchNational Lung Screening TrialLung cancerBATTLE TrialHigh riskLow-dose helical computed tomographyLung Cancer Elimination (BATTLE) trialMolecular driversMD Anderson Cancer CenterUntreated lung cancerAdvanced lung cancerFive-year survivalAdvanced cancer settingLung cancer patientsCore needle biopsyLung cancer developmentNovel trial designsAnderson Cancer CenterPatient treatment selectionFresh tumor biopsiesHelical computed tomographyEarly-stage cancerNumber one causeOptimal drug combinationsRefractory patientsPrevention setting
2011
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE Trial: Personalizing Therapy for Lung Cancer. Cancer Discovery 2011, 1: 44-53. PMID: 22586319, PMCID: PMC4211116, DOI: 10.1158/2159-8274.cd-10-0010.Peer-Reviewed Original ResearchConceptsLung cancer patientsCancer patientsNon-small cell lung cancer patientsLung Cancer Elimination (BATTLE) trialCell lung cancer patientsDisease control rateCore needle biopsy specimensLung cancer clinical trialsSpecific patient populationsLung cancer therapyNeedle biopsy specimensCancer clinical trialsRelevant molecular biomarkersKRAS patientsNSCLC patientsPatient populationRandomization periodControl rateLaboratory findingsLung cancerBiopsy specimensClinical trialsTargeted therapyBATTLE TrialIndividualized treatment
2010
Measurement of conatumumab‐induced apoptotic activity in tumors by fine needle aspirate sampling
Zoog SJ, Y. C, Kaplan‐Lefko P, Hawkins JM, Moriguchi J, Zhou L, Pan Y, Hsu C, Friberg G, Herbst R, Hill J, Juan G. Measurement of conatumumab‐induced apoptotic activity in tumors by fine needle aspirate sampling. Cytometry Part A 2010, 77A: 849-860. PMID: 20623688, DOI: 10.1002/cyto.a.20940.Peer-Reviewed Original ResearchConceptsFine needle aspiratesDeath receptor 5Needle aspiratesNonsmall cell lung cancer patientsCell lung cancer patientsCaspase-3 activationLung cancer patientsTumor necrosis factorCaspase-3Tumor-bearing miceTumor cell deathReceptor therapyPharmacodynamic markersCancer patientsDrug exposureClinical trialsCaspase 3/7 activityNecrosis factorColo205 xenograftsClinical investigationReceptor 5FNA biopsyTumor typesPharmacological impactClinical settingTreatment with HIF-1α Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice
Jacoby JJ, Erez B, Korshunova MV, Williams RR, Furutani K, Takahashi O, Kirkpatrick L, Lippman SM, Powis G, O'Reilly MS, Herbst RS. Treatment with HIF-1α Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice. Journal Of Thoracic Oncology 2010, 5: 940-949. PMID: 20512076, PMCID: PMC3782111, DOI: 10.1097/jto.0b013e3181dc211f.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAnimalsApoptosisBlotting, WesternCarcinoma, Non-Small-Cell LungDisease ProgressionHumansHypoxia-Inducible Factor 1, alpha SubunitImmunoenzyme TechniquesLung NeoplasmsLymphatic MetastasisMaleMiceMice, NudeMustard CompoundsPhenylpropionatesSmall Cell Lung CarcinomaSurvival RateTreatment OutcomeTumor Cells, CulturedConceptsLung tumor volumePX-478Tumor volumeLung cancerNSCLC modelsLung adenocarcinomaNon-small cell lung cancer xenograftsSmall cell lung cancer modelCell lung cancer xenograftsHuman small cell lung cancerSmall cell lung cancerCell lung cancer modelsPhase I clinical trialPX-478 treatmentAntitumor activityDaily oral treatmentMedian survival durationVehicle-treated groupCell lung cancerLung cancer xenograftsLung cancer patientsLung adenocarcinoma cell modelsLung cancer cell linesLung cancer modelOrthotopic mouse model
2009
VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab
Carbone DP, Salmon JS, Billheimer D, Chen H, Sandler A, Roder H, Roder J, Tsypin M, Herbst RS, Tsao AS, Tran HT, Dang TP. VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer 2009, 69: 337-340. PMID: 20036440, PMCID: PMC2891357, DOI: 10.1016/j.lungcan.2009.11.019.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, Non-Small-Cell LungDisease ProgressionDisease-Free SurvivalErlotinib HydrochlorideFemaleHumansLung NeoplasmsMaleMass SpectrometryMiddle AgedNeoplasm Recurrence, LocalPrecision MedicinePredictive Value of TestsProteomeQuinazolinesConceptsNon-small cell lung cancer patientsCell lung cancer patientsAdvanced NSCLC patientsCombination of erlotinibLung cancer patientsToxic regimenNSCLC patientsPretreatment serumCancer patientsWorse outcomesProteomic classifierBlinded mannerPatientsErlotinibBevacizumabVeriStratSurvivalTreatmentRegimenProgressionSerumTumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514
Bahleda R, Soria J, Harbison C, Park J, Felip E, Hanna N, Laurie S, Armand J, Shepherd F, Herbst R. Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514. Journal Of Clinical Oncology 2009, 27: 8098-8098. DOI: 10.1200/jco.2009.27.15_suppl.8098.Peer-Reviewed Original ResearchBMS-690514Skin rashPD biomarkersSkin biopsiesKRAS mutationsPhase I/II studyNon-small cell lung cancer patientsReversible acute renal insufficiencyRandomized phase II trialCell lung cancer patientsEGFR T790M mutationAdequate organ functionOral selective inhibitorDisease control rateAcute renal insufficiencyPhase I portionPhase II trialLung cancer patientsT790M mutationSubsequent surgical removalAnti-tumor activityEGFR copy numberEGFR T790MECOG PSEligible patients
2008
Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy
Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn PA, Varella-Garcia M, Gandara DR. Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy. Journal Of Clinical Oncology 2008, 26: 3351-3357. PMID: 18612151, PMCID: PMC3368372, DOI: 10.1200/jco.2007.14.0111.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnalysis of VarianceAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinoma, Non-Small-Cell LungCetuximabFemaleGene Expression Regulation, NeoplasticGenes, erbB-1HumansIn Situ HybridizationIn Situ Hybridization, FluorescenceLung NeoplasmsMaleMiddle AgedMultivariate AnalysisNeoplasm StagingPatient SelectionPredictive Value of TestsPrognosisProportional Hazards ModelsReference ValuesRisk AssessmentSurvival AnalysisTreatment OutcomeConceptsCell lung cancer patientsLung cancer patientsFISH-negative patientsEGFR FISHNSCLC patientsCancer patientsSurvival timeMedian progression-free survival timeProgression-free survival timeEGFR tyrosine kinase inhibitorsDisease control rateChemotherapy-naive patientsAdvanced-stage NSCLCMedian survival timeEpidermal growth factor receptor (EGFR) gene copy numberFISH-positive patientsAvailable tumor tissueEGFR gene copy numberTyrosine kinase inhibitorsFISH-positive tumorsPhase II selection trialFISH-positive groupConcurrent chemotherapyConcurrent therapyPredictive factorsBATTLE: Biomarker-Based Approaches of Targeted Therapy for Lung Cancer Elimination
Hong W, Herbst R, Mao L, Kim E. BATTLE: Biomarker-Based Approaches of Targeted Therapy for Lung Cancer Elimination. 2008 DOI: 10.21236/ada485729.Peer-Reviewed Original ResearchNonsmall cell lung cancerLung cancerTargeted therapyAdvanced nonsmall cell lung cancerEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsReceptor tyrosine kinase inhibitorsLung Cancer EliminationTumor response rateCell lung cancerLung cancer patientsCancer-related deathTyrosine kinase inhibitorsCancer patientsCancer eliminationEGFR mutationsTherapeutic approachesResponse rateCancerCancer typesPatientsKinase inhibitorsTherapyInitial successChemotherapy